Scholarlink

Background <p>The COVID-19 pandemic, among others, has shown the world that rapid drug and vaccine development and expedited clinical trials can be effective and safe. The overall benefit of accelerating clinical development would be faster public access to medicines. In this study, we explore key stakeholders’ experiences and perceptions of drivers for the acceleration of clinical development.</p> Methods <p>We conducted semi-structured interviews with policy advisors and experts from key stakeholder groups involved in clinical development, identified via a power-interest stakeholder analysis. Thematic analysis was used to identify analytic themes.</p> Results <p>Twenty-five participants were interviewed representing pharmaceutical companies, the European Medicines Agency, national competent authorities in the EU, different research and clinical development organizations, including non-governmental organizations, and the World Health Organization. Drivers facilitating acceleration of clinical development could be grouped into three themes: alignment of stakeholders, innovative research design and processes, and financing. Some barriers of systematic acceleration were raised within these themes: European disharmony in trials practice, regulations and guidance; fragmentation of efforts; bureaucracy and the complexity of the Clinical Trials Information System (CTIS) submission process; and financial neglect for poverty-related diseases.</p> Conclusion <p>To sustainably accelerate clinical development, future policies should facilitate collaboration and communication between stakeholders and work to minimize technical and bureaucratic barriers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Building a case for accelerated clinical development of drugs and vaccines – what are the driving forces?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Loïs C. van Eck,
  • Clàudia Pallisé Perelló,
  • Natalie Evans,
  • Mariëtte A. van den Hoven,
  • Martin P. Grobusch,
  • Sabine M. Hermans,
  • Hanna K. de Jong

摘要

Background

The COVID-19 pandemic, among others, has shown the world that rapid drug and vaccine development and expedited clinical trials can be effective and safe. The overall benefit of accelerating clinical development would be faster public access to medicines. In this study, we explore key stakeholders’ experiences and perceptions of drivers for the acceleration of clinical development.

Methods

We conducted semi-structured interviews with policy advisors and experts from key stakeholder groups involved in clinical development, identified via a power-interest stakeholder analysis. Thematic analysis was used to identify analytic themes.

Results

Twenty-five participants were interviewed representing pharmaceutical companies, the European Medicines Agency, national competent authorities in the EU, different research and clinical development organizations, including non-governmental organizations, and the World Health Organization. Drivers facilitating acceleration of clinical development could be grouped into three themes: alignment of stakeholders, innovative research design and processes, and financing. Some barriers of systematic acceleration were raised within these themes: European disharmony in trials practice, regulations and guidance; fragmentation of efforts; bureaucracy and the complexity of the Clinical Trials Information System (CTIS) submission process; and financial neglect for poverty-related diseases.

Conclusion

To sustainably accelerate clinical development, future policies should facilitate collaboration and communication between stakeholders and work to minimize technical and bureaucratic barriers.